Future perspectives in myasthenia gravis (Review) DOI Creative Commons
Rebecca Golfinopoulou, Eleni Papakonstantinou, Dimitriοs Vlachakis

и другие.

Deleted Journal, Год журнала: 2023, Номер 3(1)

Опубликована: Май 30, 2023

Myasthenia gravis (MG) is a rare, highly polygenic autoimmune disease mainly caused by target‑specific pathogenic antibodies, and its fluctuating course through the patient's life, often entails hospitalizations difficulties in everyday life. The pathophysiology of MG complex with number contributing factors, involving genetic, epigenetic environmental factors are responsible for limited immune tolerance. This heterogenic appears to have common genetic background other diseases single nucleotide polymorphisms (SNPs) been found be associated different forms genome‑wide association studies; i.e, cholinergic receptor nicotinic alpha 1 subunit (CHRNA1) that encodes α acetylcholine includes SNP allele MG. Additionally, specific genes or even genomic regions can differentiated set including methylations, non‑coding RNAs histone modifications. role epigenetics has reported monozygotic twin studies, where combination methylations numerous small changes gene expression shown contribute development disease, demonstrating stronger predisposition Establishing realm further promote basic research novel therapeutic approaches used overcome limitations current clinical practices.

Язык: Английский

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis DOI Creative Commons
Hui Chen

Frontiers in Pharmacology, Год журнала: 2025, Номер 15

Опубликована: Янв. 23, 2025

Background Ofatumumab, a fully human monoclonal antibody targeting CD20, is approved for the treatment of relapsing multiple sclerosis. Comprehensive real-world safety data are crucial informing clinical practice. Methods The FDA Adverse Event Reporting System database was utilized to perform disproportionality analysis, covering reports from Q3 2020 Q2 2024, in which ofatumumab identified as primary suspected drug. Statistical approaches used included Odds Ratio, Proportional Bayesian Confidence Propagation Neural Network, and Multi-item Gamma Poisson Shrinker. timing adverse events assessed using Weibull distribution model highlight temporal risk patterns. Results Known reactions, such injection site reactions upper respiratory tract infections, displayed positive signals. Additionally, novel off-label events, including brain fog, muscle spasms, mood alterations, were identified, marking first evidence these potential risks. Temporal analysis revealed that most occurred within month treatment, indicating an early phase. Subgroup demonstrated notable differences event profiles by gender age, with males more prone hyperhidrosis older patients susceptible neurological symptoms. Conclusion This provides important insights, confirming known identifying additional Early tailored monitoring protocols during initial phase, regular psychiatric assessments, recommended optimize patient outcomes. Prospective studies validate results explore underlying mechanisms.

Язык: Английский

Процитировано

0
ESCLEROSIS MULTIPLE Y ENFERMEDADES REUMATOLOGICAS: Behçet, Sarcoidosis, Sjögren. DOI Creative Commons

Y. Contreras,

Bernardo González, Mónica Hernández

и другие.

Neurology Perspectives, Год журнала: 2025, Номер unknown, С. 100198 - 100198

Опубликована: Май 1, 2025

Процитировано

0
Systematic review and meta-analysis of preclinical studies DOI
Benjamin V. Ineichen, Ulrike Held, Georgia Salanti

и другие.

Nature Reviews Methods Primers, Год журнала: 2024, Номер 4(1)

Опубликована: Окт. 3, 2024

Язык: Английский

Процитировано

2
Future perspectives in myasthenia gravis (Review) DOI Creative Commons
Rebecca Golfinopoulou, Eleni Papakonstantinou, Dimitriοs Vlachakis

и другие.

Deleted Journal, Год журнала: 2023, Номер 3(1)

Опубликована: Май 30, 2023

Myasthenia gravis (MG) is a rare, highly polygenic autoimmune disease mainly caused by target‑specific pathogenic antibodies, and its fluctuating course through the patient's life, often entails hospitalizations difficulties in everyday life. The pathophysiology of MG complex with number contributing factors, involving genetic, epigenetic environmental factors are responsible for limited immune tolerance. This heterogenic appears to have common genetic background other diseases single nucleotide polymorphisms (SNPs) been found be associated different forms genome‑wide association studies; i.e, cholinergic receptor nicotinic alpha 1 subunit (CHRNA1) that encodes α acetylcholine includes SNP allele MG. Additionally, specific genes or even genomic regions can differentiated set including methylations, non‑coding RNAs histone modifications. role epigenetics has reported monozygotic twin studies, where combination methylations numerous small changes gene expression shown contribute development disease, demonstrating stronger predisposition Establishing realm further promote basic research novel therapeutic approaches used overcome limitations current clinical practices.

Язык: Английский

Процитировано

1